Application of Circulating Tumor Cells in Peripheral Blood in Judging the Prognosis of Patients with Renal Cancer and Related Indexes of Blood Coagulation
- 1 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 2 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 3 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 4 Department of Oncology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 5 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 6 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 7 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
- 8 Department of Urology, Affiliated Hospital of Chengde Medical College, Chengde, China
Abstract
Objective: To investigate the value of the number of circulating tumor cells (CTC) in peripheral blood in the prognosis and coagulation-related indicators of patients with renal cancer. Methods: 65 patients with renal cell carcinoma (RCC) confirmed pathologically were divided into CTC positive group and CTC negative group according to the CTC count (5 pcs/3.5 ml). Compare the age, gender, tumor location, TNM (clinical stage), pathological grade, tissue type, lymph node metastasis, distant metastasis, prognosis and prothrombin time (PT), fibrinogen (FIB), partial coagulation of the two groups of patients The correlation between the results of zymogen time (APTT) and D-dimer (DD) and the number of CTC. Results: There were significant differences in TNM, lymph node metastasis, and distant metastasis between the two groups (P < 0.05). The number of CTC in patients was correlated with FIB and D-D levels (P < 0.05). Conclusion: The number of CTC in patients with renal cell carcinoma is correlated with some clinical phenotypes (TNM, lymph node metastasis, distant metastasis) and some coagulation indexes (FIB, D-D), and can jointly predict the prognosis of renal cancer.
- Brookman-May, S.D., May, M., et al. (2013) Time to Recurrence is a Significant Predictor of Cancer Spcific Survival after Recurrence in Patients with Recurrent Renal Cell Carcinoma-Results from a Comprehrnsive Multi-Centre Database (CORONA/SATURN-Project). BJU International, 112, 909-916. https://doi.org/10.1111/bju.12246
- Zhao, W., Liu, Y., Jenkins, B.D., Cheng, R., Harris, B.N., Zhang, W., Xie, J., Murrow, J.R., Hodgson, J., Egan, M., et al. (2019) Tumor Antigen-Independent and Cell Size Variation-Inclusive Enrichment of Viable Circulating Tumor Cells. Lab Chip, 19, 1860-1876. https://doi.org/10.1039/C9LC00210C
- Plaks, V., Koopman, C.D. and Werb, Z. (2013) Cancer. Circulating Tumor Cells. Science, 341, 1186-1188. https://doi.org/10.1126/science.1235226
- Lorente, D., Olmos, D., Mateo, J., Dolling, D., Bianchini, D., Seed, G., Flohr, P., Crespo, M., Figueiredo, I., Miranda, S., et al. (2018) Circulating Tumour Cell Increase as a Biomarker of Disease Progression in Metastatic Castration-Resistant Prostate Cancer Patients with Low Baseline CTC Counts. Annals of Oncology, 29, 1554-1560. https://doi.org/10.1093/annonc/mdy172
- Xu, H.T., Miao, J., Liu, J.W., Zhang, L.G. and Zhang, Q.G. (2017) Prognostic Value of Circulating Tumor Cells in Esophageal Cancer. World Journal of Gastroenterology, 23, 1310-1318. https://doi.org/10.3748/wjg.v23.i7.1310
- Reid, A.H., Attard, G., Danila, D.C., et al. (2010) Significant and Sustained Antitumor Activity in Post-Docetaxel, Castrationresistant Prostate Cancer with the CYP17 Inhibitor Abiraterone Acetate. Journal of Clinical Oncology, 28, 1489-1495. https://doi.org/10.1200/JCO.2009.24.6819
- Rasmussen, F. (2013) Metastatic Renal Cell Cancer. Cancer Imaging, 13, 374-380. https://doi.org/10.1102/1470-7330.2013.9035
- Benezeder, T., Tiran, V., Treitler, A.A.N., et al. (2017) Mulrigene Methylation Analysis of Enriched Circulating Tumor Cells Associates with Poor Progresion-Free Survival in Metastatic Breast Cancer Patients. Oncotarget, 8, 92483-92496. https://doi.org/10.18632/oncotarget.21426
- Wallwiener, M., Riethdorf, S., Hartkopf, A.D., Modugno, C., Nees, J., Madhavan, D., Sprick, M.R., Schott, S., Domschke, C., Baccelli, I., et al. (2014) Serial Enumeration of Circulating Tumor Cells Predicts Treatment Response and Prognosis in Metastatic Breast Cancer: A Prospective Study in 393 Patients. BMC Cancer, 14, Article No. 512. https://doi.org/10.1186/1471-2407-14-512
- Cristofanilli, M., Pierga, J.Y., Reuben, J., Rademaker, A., Davis, A.A., Peeters, D.J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., et al. (2019) The Clinical Use of Circulating Tumor Cells (CTCs) Enumeration for Staging of Metastatic Breast Cancer (MBC): International Expert Consensus Paper. Critical Reviews in Oncology/Hematology, 134, 39-45. https://doi.org/10.1016/j.critrevonc.2018.12.004